← Leaderboards
Li Jia
Brigham And Women'S Hospital
$4,130,520
Attributed
$4,130,520
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,130,520 · 4
By mechanism
R01$3,218,378 · 2
R21$912,142 · 2
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Fiona Fennessy$4,420,567
- Mark A. Rubin$21,732,421
- Stephan E Maier$7,745,020
- Charles J Dimitroff$9,730,798
- Kullervo Hynynen$20,293,002
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingMalignant Neoplasm Of ProstateTumorFutureAndrogen ReceptorProstate Cancer CellNew Therapeutic TargetProteinsTargeted TreatmentMutationProstate Cancer ModelResistancePoly(Adp-Ribose) PolymerasesEnzymesAbirateroneGeneticGenesGenerationsCancer PatientPathway InteractionsEnzalutamideInhibitorReceptor SignalingMutate
Grant awards (12)
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer$409,463
R01 · FY2025 · CA · contact PI
MMS22L loss and PARP inhibition in prostate cancer$409,463
R01 · FY2025 · CA · contact PI
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer$388,990
R01 · FY2024 · CA · contact PI
MMS22L loss and PARP inhibition in prostate cancer$388,990
R01 · FY2024 · CA · contact PI
MMS22L loss and PARP inhibition in prostate cancer$409,463
R01 · FY2023 · CA · contact PI
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer$401,273
R01 · FY2023 · CA · contact PI
CHEK2 loss promotes prostate cancer resistance to PARP inhibitors$205,023
R21 · FY2023 · CA · contact PI
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer$401,273
R01 · FY2022 · CA · contact PI
CHEK2 loss promotes prostate cancer resistance to PARP inhibitors$251,048
R21 · FY2022 · CA · contact PI
RNASEH2B loss to predict response to PARP inhibitor in prostate cancer$205,023
R21 · FY2022 · CA · contact PI
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer$409,463
R01 · FY2021 · CA · contact PI
RNASEH2B loss to predict response to PARP inhibitor in prostate cancer$251,048
R21 · FY2021 · CA · contact PI